Benitec Biopharma Inc. (BNTC)
NASDAQ: BNTC · Real-Time Price · USD
8.49
-0.25 (-2.86%)
Nov 2, 2026, 4:00 PM EST - Market closed
Benitec Biopharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
24
Market Cap
296.15M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | - | - | - |
| Jun 30, 2025 | - | - | - |
| Jun 30, 2024 | - | - | - |
| Jun 30, 2023 | 75.00K | 2.00K | 2.74% |
| Jun 30, 2022 | 73.00K | 14.00K | 23.73% |
| Jun 30, 2021 | 59.00K | -43.00K | -42.16% |
| Jun 30, 2020 | 102.00K | -12.10M | -99.16% |
| Jun 30, 2019 | 12.20M | 8.81M | 259.85% |
| Jun 30, 2018 | 3.39M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Agenus | 132.69M |
| Enanta Pharmaceuticals | 65.26M |
| vTv Therapeutics | 36.84M |
| Scribe Therapeutics | 33.30M |
| Arcturus Therapeutics Holdings | 29.37M |
| Alector | 13.86M |
| Opus Genetics | 9.86M |
| SAB Biotherapeutics | 114.70K |
BNTC News
- 5 days ago - Benitec Biopharma announces interim results from BB-301 trial - TheFly
- 5 days ago - Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 - GlobeNewsWire
- 10 days ago - Benitec Biopharma initiated with an Outperform at Raymond James - TheFly
- 13 days ago - Benitec Biopharma Proxy statement: Proxy filing - Filings
- 13 days ago - Benitec Biopharma Proxy statement: Proxy filing - Filings
- 4 weeks ago - Benitec Biopharma says BB-301 pivotal still on track for mid-2027 - TheFly
- 4 weeks ago - Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study - GlobeNewsWire
- 6 weeks ago - Benitec Biopharma price target raised to $17 from $16 at Wedbush - TheFly